IR@PKUHSC  > 北京大学药学院
学科主题药学
In Vivo Evaluation of Silybin Nanosuspensions Targeting Liver
Wang, Yancai1; Wang, Lianqin2; Liu, Zhaoping3; Zhang, Dianrui3; Zhang, Qiang4
关键词Silybin Nanosuspensions Biodistribution Pharmacodynamics Targeting Delivery
刊名JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
2012-10-01
DOI10.1166/jbn.2012.1444
8期:5页:760-769
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Nanoscience & Nanotechnology ; Medicine, Research & Experimental
研究领域[WOS]Science & Technology - Other Topics ; Research & Experimental Medicine
关键词[WOS]LIPID NANOPARTICLES ; TISSUE DISTRIBUTION ; DRUG NANOCRYSTALS ; RAT-LIVER ; DELIVERY ; DAMAGE ; INHIBITION ; PHARMACOKINETICS ; DIHEMISUCCINATE ; BIOAVAILABILITY
英文摘要

The present study investigated the production, in vivo biodistribution and hepatoprotective of two formulated silybin nanosuspensions with different particle size. The physicochemical properties of the two formulated silybin nanosuspensions were investigated by TEM, AFM and SEM. A kinetic study was conducted to evaluate the influence of particle size on the in vivo tissue distribution following intravenous administration in the mice. The in vivo hepatoprotective studies were conducted on beagle dogs with optimized setting. A clear physicochemical difference was observed among the silybin solution, larger particles and the small particles. The formulation of larger particle size was preferentially targeted at liver and spleen. The silybin nanosuspensions, administrated either intravenously or orally, presented significant (P <= 0.05) hepatoprotective effect by reducing the serum marker enzymes such as AST, ALT, ALP, TBIL and GGT. Histopathological study further confirmed the hepatoprotective activity of the two silybin nanosuspensions formulations when compared with the CCl4 treated control group. These results indicate that the nanosuspensions approaches could be used to improve the drug target delivery and therapeutic efficacy of the silybin.

语种英语
WOS记录号WOS:000306941400006
项目编号2009CB930300 ; 2009ZX09502-001
资助机构National Basic Research Program of China (973 Program) ; technological specialized project for Significant New Formulation of New Drugs
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57561
专题北京大学药学院
北京大学药学院_药剂学系
作者单位1.Shandong Polytech Univ, Sch Chem & Pharmaceut Engn, Jinan 250353, Peoples R China
2.Hosp Shandong Polytech Univ, Jinan 250353, Peoples R China
3.Shandong Univ, Coll Pharm, Jinan 250012, Peoples R China
4.Peking Univ, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Wang, Yancai,Wang, Lianqin,Liu, Zhaoping,et al. In Vivo Evaluation of Silybin Nanosuspensions Targeting Liver[J]. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY,2012,8(5):760-769.
APA Wang, Yancai,Wang, Lianqin,Liu, Zhaoping,Zhang, Dianrui,&Zhang, Qiang.(2012).In Vivo Evaluation of Silybin Nanosuspensions Targeting Liver.JOURNAL OF BIOMEDICAL NANOTECHNOLOGY,8(5),760-769.
MLA Wang, Yancai,et al."In Vivo Evaluation of Silybin Nanosuspensions Targeting Liver".JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 8.5(2012):760-769.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Yancai]的文章
[Wang, Lianqin]的文章
[Liu, Zhaoping]的文章
百度学术
百度学术中相似的文章
[Wang, Yancai]的文章
[Wang, Lianqin]的文章
[Liu, Zhaoping]的文章
必应学术
必应学术中相似的文章
[Wang, Yancai]的文章
[Wang, Lianqin]的文章
[Liu, Zhaoping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。